Factor ix recombinant nos
Products billed under this code include Benefix.
Payment limit per 1 IU, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Benefix.
Payment limit per 1 IU, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Benefix | Pfizer Inc | 58394-0633-03 | 1 | $1.868 |
| Benefix | Pfizer Inc | 58394-0634-03 | 1 | $1.868 |
| Benefix | Pfizer Inc | 58394-0635-03 | 1 | $1.868 |
| Benefix | Pfizer Inc | 58394-0636-03 | 1 | $1.868 |
| Benefix | Pfizer Inc | 58394-0637-03 | 1 | $1.868 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $1.868 | +$0.004 | 1 IU | Factor ix recombinant nos | v1, posted September 17, 2026 |
| 3Q26 | $1.864 | +$0.028 | 1 IU | Factor ix recombinant nos | v1, posted September 15, 2026 |
| 2Q26 | $1.836 | +$0.002 | 1 IU | Factor ix recombinant nos | v1, posted September 15, 2026 |
| 1Q26 | $1.834 | −$0.015 | 1 IU | Factor ix recombinant nos | v1, posted September 15, 2026 |
| 4Q25 | $1.849 | −$0.026 | 1 IU | Factor ix recombinant nos | v1, posted September 8, 2026 |
| 3Q25 | $1.875 | +$0.027 | 1 IU | Factor ix recombinant nos | v1, posted March 10, 2026 |
| 2Q25 | $1.848 | +$0.008 | 1 IU | Factor ix recombinant nos | v1, posted March 10, 2026 |
| 1Q25 | $1.84 | −$0.012 | 1 IU | Factor ix recombinant nos | v1, posted December 19, 2025 |
| 4Q24 | $1.852 | +$0.013 | 1 IU | Factor ix recombinant nos | v1, posted June 11, 2025 |
| 3Q24 | $1.839 | +$0.087 | 1 IU | Factor ix recombinant nos | v1, posted June 11, 2025 |
| 2Q24 | $1.752 | +$0.001 | 1 IU | Factor ix recombinant nos | v1, posted March 11, 2025 |
| 1Q24 | $1.751 | +$0.007 | 1 IU | Factor ix recombinant nos | v1, posted December 19, 2024 |
| 4Q23 | $1.744 | −$0.012 | 1 IU | Factor ix recombinant nos | v1, posted October 10, 2024 |
| 3Q23 | $1.756 | +$0.111 | 1 IU | Factor ix recombinant nos | v1, posted June 5, 2024 |
| 2Q23 | $1.645 | −$0.001 | 1 IU | Factor ix recombinant nos | v1, posted February 23, 2024 |
| 1Q23 | $1.646 | +$0.016 | 1 IU | Factor ix recombinant nos | v1, posted December 6, 2023 |
| 4Q22 | $1.63 | −$0.001 | 1 IU | Factor ix recombinant nos | v1, posted June 22, 2023 |
| 3Q22 | $1.631 | +$0.047 | 1 IU | Factor ix recombinant nos | v1, posted June 9, 2023 |
| 2Q22 | $1.584 | −$0.006 | 1 IU | Factor ix recombinant nos | v1, posted December 14, 2022 |
| 1Q22 | $1.59 | −$0.017 | 1 IU | Factor ix recombinant nos | v1, posted June 8, 2022 |
| 4Q21 | $1.607 | +$0.019 | 1 IU | Factor ix recombinant nos | v1, posted June 2, 2022 |
| 3Q21 | $1.588 | +$0.033 | 1 IU | Factor ix recombinant nos | v1, posted June 2, 2022 |
| 2Q21 | $1.555 | +$0.023 | 1 IU | Factor ix recombinant nos | v1, posted March 1, 2022 |
| 1Q21 | $1.532 | – | 1 IU | Factor ix recombinant nos | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.